2020 World Chronic Wounds Pipeline Insight
Aug 28, 2020, 07:00 ET
DUBLIN, Aug. 28, 2020 /PRNewswire/ -- The "Chronic Wounds - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The "Chronic Wounds Pipeline Insight, 2020" report provides comprehensive insights of the current clinical development scenario and growth prospects across the Chronic Wounds market. A detailed picture of the Chronic Wounds pipeline landscape is provided, which includes the disease overview and Chronic Wounds treatment guidelines. The assessment part of the report embraces in-depth Chronic Wounds commercial assessment and clinical assessment of the Chronic Wounds pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals and product development activities comprising the technology, Chronic Wounds collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
- All the companies that are developing therapies for the treatment of Chronic Wounds with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Chronic Wounds treatment.
- Chronic Wounds key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Chronic Wounds market.
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
Scope of the report
- The Chronic Wounds report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Chronic Wounds across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Chronic Wounds therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Chronic Wounds research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Chronic Wounds .
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Chronic Wounds .
- In the coming years, the Chronic Wounds market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Chronic Wounds R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Chronic Wounds treatment market. Several potential therapies for Chronic Wounds are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Chronic Wounds market size in the coming years.
Key Topics Covered:
1. Report Introduction
2. Chronic Wounds
3. Chronic Wounds Current Treatment Patterns
4. Chronic Wounds - Analytical Perspective
5. Therapeutic Assessment
6. Chronic Wounds Late Stage Products (Phase-III)
7. Chronic Wounds Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Wounds Discontinued Products
13. Chronic Wounds Product Profiles
14. Chronic Wounds Key Companies
15. Chronic Wounds Key Products
16. Dormant and Discontinued Products
17. Chronic Wounds Unmet Needs
18. Chronic Wounds Future Perspectives
19. Chronic Wounds Analyst Review
20. Appendix
21. Report Methodology
Companies Mentioned
- Antria
- RHEACELL Gm
- Ticeba GmbH
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mw6yx6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
